We are thrilled to announce the publication of a 10-day study conducted by Charles River, comparing Kytopen’s Flowfect Tx™ cellular engineering platform with two commercially available electroporation platforms.
A key finding in this study was the considerably higher yields of gene-edited, viable cells with the Flowfect Tx™ platform.
“We have a GMP-scale manufacturing platform that has already been evaluated for tech transfer and this study further highlights the ease of implementation to develop superior yields of final drug substance", said Kevin Gutshall, Chief Commercial Officer at Kytopen.
To access the full press release: https://lnkd.in/gJnfCgMX
To access the summary of the study, Making Gains in Non-Viral Engineering of T Cells for Cell Manufacturing, visit https://bit.ly/3ANGxxF
#celltherapy #regenerativemedicine #tcells #cancer #cancerresearch #geneediting #innovation
Chief Technology Officer at Gamma Biosciences
6moLooking forward to (re)connecting! See you there!